{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:40:37Z","timestamp":1779316837961,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","ejradiology.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejrad.2024.111632","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T17:56:10Z","timestamp":1721066170000},"page":"111632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Baseline 18F-FDG PET\/CT may contribute to the determination of initial treatment strategy for newly diagnosed follicular lymphoma"],"prefix":"10.1016","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8959-6696","authenticated-orcid":false,"given":"Qiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5787-1136","authenticated-orcid":false,"given":"Yaping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejrad.2024.111632_b0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","volume":"5","author":"Carbone","year":"2019","journal-title":"Follicular Lymphoma. Nat Rev Dis Primers."},{"key":"10.1016\/j.ejrad.2024.111632_b0010","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"Jacobsen","year":"2022","journal-title":"Am J Hematol."},{"key":"10.1016\/j.ejrad.2024.111632_b0015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ejrad.2024.111632_b0020","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2015-11-632745","article-title":"Is watch and wait still acceptable for patients with low-grade follicular lymphoma?","volume":"127","author":"Armitage","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.ejrad.2024.111632_b0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/bjh.13316","article-title":"A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait","volume":"169","author":"El-Galaly","year":"2015","journal-title":"Br J Haematol."},{"key":"10.1016\/j.ejrad.2024.111632_b0030","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"The Lancet Oncology."},{"key":"10.1016\/j.ejrad.2024.111632_b0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14397595.2018.1554321","article-title":"IgG4-related kidney disease and retroperitoneal fibrosis: An update","volume":"29","author":"Kawano","year":"2019","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.ejrad.2024.111632_b0040","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","article-title":"Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database","volume":"30","author":"Solal-C\u00e9ligny","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ejrad.2024.111632_b0045","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ejrad.2024.111632_b0050","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.ejrad.2024.111632_b0055","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ejrad.2024.111632_b0060","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clml.2016.11.004","article-title":"Improving Survival of Patients With Hodgkin Lymphoma Over 4 Decades: Experience of the British National Lymphoma Investigation (BNLI) With 6834 Patients","volume":"17","author":"Kwan","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ejrad.2024.111632_b0065","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0936-6555(98)80003-4","article-title":"The BNLI: past and present. British National Lymphoma Investigation","volume":"10","author":"Hudson","year":"1998","journal-title":"Clin Oncol (r Coll Radiol)."},{"key":"10.1016\/j.ejrad.2024.111632_b0070","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"The Lancet Haematology."},{"key":"10.1016\/j.ejrad.2024.111632_b0075","doi-asserted-by":"crossref","first-page":"20140360","DOI":"10.1259\/bjr.20140360","article-title":"Impact of (18)F-FDG PET\/CT on the staging and management of follicular lymphoma","volume":"87","author":"Metser","year":"2014","journal-title":"Br J Radiol."},{"key":"10.1016\/j.ejrad.2024.111632_b0080","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/annonc\/mdt562","article-title":"The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)","volume":"25","author":"Luminari","year":"2014","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ejrad.2024.111632_b0085","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1007\/s00330-022-08624-7","article-title":"Baseline [18F]FDG PET\/CT may predict the outcome of newly diagnosed follicular lymphoma in patients managed with initial \u201cwatch-and-wait\u201d approach","volume":"32","author":"Yang","year":"2022","journal-title":"Eur Radiol."},{"key":"10.1016\/j.ejrad.2024.111632_b0090","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ejrad.2024.111632_b0095","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/RLU.0b013e318217aeff","article-title":"F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis","volume":"36","author":"Chen","year":"2011","journal-title":"Clin Nucl Med."},{"key":"10.1016\/j.ejrad.2024.111632_b0100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2011.08969.x","article-title":"Guidelines on the investigation and management of follicular lymphoma","volume":"156","author":"McNamara","year":"2012","journal-title":"Br J Haematol."},{"key":"10.1016\/j.ejrad.2024.111632_b0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.23372","article-title":"SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma","volume":"88","author":"Zinzani","year":"2013","journal-title":"Am J Hematol."},{"key":"10.1016\/j.ejrad.2024.111632_b0110","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/annonc\/mds517","article-title":"ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)","volume":"24","author":"Ghielmini","year":"2013","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ejrad.2024.111632_b0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clml.2014.07.015","article-title":"A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board","volume":"15","author":"Kuruvilla","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ejrad.2024.111632_b0120","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.ejrad.2024.111632_b0125","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.2147\/CMAR.S216445","article-title":"Prognostic values of baseline, interim and end-of therapy 18F-FDG PET\/CT in patients with follicular lymphoma","volume":"11","author":"Zhou","year":"2019","journal-title":"CMAR."},{"key":"10.1016\/j.ejrad.2024.111632_b0130","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.4143\/crt.2018.649","article-title":"Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma","volume":"51","author":"Liang","year":"2019","journal-title":"Cancer Res Treat."},{"key":"10.1016\/j.ejrad.2024.111632_b0135","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline Metabolic Tumor Volume Predicts Outcome in High\u2013Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies","volume":"34","author":"Meignan","year":"2016","journal-title":"JCO."},{"key":"10.1016\/j.ejrad.2024.111632_b0140","article-title":"Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET\/CT","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.ejrad.2024.111632_b0145","article-title":"Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden","author":"Leccisotti","year":"2022","journal-title":"J Cancer Res Clin Oncol."}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X24003486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X24003486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:52:37Z","timestamp":1729126357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X24003486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":29,"alternative-id":["S0720048X24003486"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2024.111632","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline 18F-FDG PET\/CT may contribute to the determination of initial treatment strategy for newly diagnosed follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2024.111632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111632"}}